Pharyngeal instillation of surfactant before the first breath for prevention of morbidity and mortality in preterm infants at risk of respiratory distress syndrome

Aerosolized Surfactants, Anti-Inflammatory Drugs, and Analgesics

“…I think many people have circumvented that and have placed thin catheters down into the airway while the baby's still on CPAP, 4 or they deliver a bolus of surfactant to the babies as they present at the perineum during birth. There is also another minimally invasive method described in the literature, 5 wherein a bolus of surfactant is delivered retropharyngeally to babies as they present during birth, and with the first breath, the drug can be aspirated into the lungs. Evidence from animal and observational human studies suggests that pharyngeal instillation of surfactant before the first breath is potentially safe and feasible and may be effective.…”

Aerosolized Surfactants, Anti-Inflammatory Drugs, and Analgesics

“…I think many people have circumvented that and have placed thin catheters down into the airway while the baby's still on CPAP, 4 or they deliver a bolus of surfactant to the babies as they present at the perineum during birth. There is also another minimally invasive method described in the literature, 5 wherein a bolus of surfactant is delivered retropharyngeally to babies as they present during birth, and with the first breath, the drug can be aspirated into the lungs. Evidence from animal and observational human studies suggests that pharyngeal instillation of surfactant before the first breath is potentially safe and feasible and may be effective.…”

Update of minimally invasive surfactant therapy

“…A feasibility and safety study of 23 preterm infants born at 27–30 weeks of gestation was done by Kattwinkel et al25) in 2004. In 2011, Cochrane Reviews showed that surfactant application into the pharynx before the first breath is potentially feasible, safe, and may be effective, but there were no well-designed randomized controlled trials60). Table 2 shows the characteristics of these human studies253233).…”

Non-Invasive Surfactant Administration in Preterm Infants

“…Available evidence suggests that oropharyngeal surfactant administration is feasible and well-tolerated, with minimal reported adverse events. However, clinical efficacy remains inconsistent, likely due to variability in surfactant aspiration and lung deposition [43]. As a result, this method remains an investigational strategy and future research on oropharyngeal delivery must focus on optimizing the dose, timing, and subgroup populations in evaluating efficacy in extremely premature infants.…”

Aerosolized Surfactants, Anti-Inflammatory Drugs, and Analgesics

“…I think many people have circumvented that and have placed thin catheters down into the airway while the baby's still on CPAP, 4 or they deliver a bolus of surfactant to the babies as they present at the perineum during birth. There is also another minimally invasive method described in the literature, 5 wherein a bolus of surfactant is delivered retropharyngeally to babies as they present during birth, and with the first breath, the drug can be aspirated into the lungs. Evidence from animal and observational human studies suggests that pharyngeal instillation of surfactant before the first breath is potentially safe and feasible and may be effective.…”

Update of minimally invasive surfactant therapy

“…A feasibility and safety study of 23 preterm infants born at 27–30 weeks of gestation was done by Kattwinkel et al25) in 2004. In 2011, Cochrane Reviews showed that surfactant application into the pharynx before the first breath is potentially feasible, safe, and may be effective, but there were no well-designed randomized controlled trials60). Table 2 shows the characteristics of these human studies253233).…”

Non-Invasive Surfactant Administration in Preterm Infants

“…Available evidence suggests that oropharyngeal surfactant administration is feasible and well-tolerated, with minimal reported adverse events. However, clinical efficacy remains inconsistent, likely due to variability in surfactant aspiration and lung deposition [43]. As a result, this method remains an investigational strategy and future research on oropharyngeal delivery must focus on optimizing the dose, timing, and subgroup populations in evaluating efficacy in extremely premature infants.…”

Aerosolized Surfactants, Anti-Inflammatory Drugs, and Analgesics

“…I think many people have circumvented that and have placed thin catheters down into the airway while the baby's still on CPAP, 4 or they deliver a bolus of surfactant to the babies as they present at the perineum during birth. There is also another minimally invasive method described in the literature, 5 wherein a bolus of surfactant is delivered retropharyngeally to babies as they present during birth, and with the first breath, the drug can be aspirated into the lungs. Evidence from animal and observational human studies suggests that pharyngeal instillation of surfactant before the first breath is potentially safe and feasible and may be effective.…”

Update of minimally invasive surfactant therapy

“…A feasibility and safety study of 23 preterm infants born at 27–30 weeks of gestation was done by Kattwinkel et al25) in 2004. In 2011, Cochrane Reviews showed that surfactant application into the pharynx before the first breath is potentially feasible, safe, and may be effective, but there were no well-designed randomized controlled trials60). Table 2 shows the characteristics of these human studies253233).…”

Non-Invasive Surfactant Administration in Preterm Infants

“…Available evidence suggests that oropharyngeal surfactant administration is feasible and well-tolerated, with minimal reported adverse events. However, clinical efficacy remains inconsistent, likely due to variability in surfactant aspiration and lung deposition [43]. As a result, this method remains an investigational strategy and future research on oropharyngeal delivery must focus on optimizing the dose, timing, and subgroup populations in evaluating efficacy in extremely premature infants.…”